CompletedPhase 3NCT00606580

Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
U.S. Army Medical Research and Development Command
Principal Investigator
Afif Ben Salah, M.D., Ph.D.
Institute Pasteur Tunisia
Intervention
WR 279,396 topical cream(drug)
Enrollment
375 target
Eligibility
5-65 years · All sexes
Timeline
2008 – 2011

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00606580 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials